Executive interview – Lavie Bio

Executive interview – Lavie Bio

Lavie Bio aims to improve food quality, sustainability and agricultural productivity through the introduction of microbiome-based ag-biological products. Using proprietary computational predictive technologies, Lavie Bio is implementing a ‘biology-driven design’ approach to introduce ‘next-generation’ bio-stimulants and bio-pesticides.

The interview features CEO Ido Dor and board member Kristian Bjørneboe.

Lavie Bio is a private subsidiary of Edison client Evogene (TASE: EVGN, NASDAQ: EVGN), a leading company in leveraging computational biology to design novel products for life science-based industries including human health, agriculture and industrial applications. To achieve its mission, Evogene established a unique Computational Predictive Biology (CPB) platform, leveraging the revolutions in big data and artificial intelligence, and incorporating a deep understanding of biology.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free